GRI Bio, Inc. (GRI)
NASDAQ: GRI · Real-Time Price · USD
1.990
+0.020 (1.02%)
At close: Jul 25, 2025, 4:00 PM
1.980
-0.010 (-0.50%)
After-hours: Jul 25, 2025, 7:48 PM EDT

Company Description

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States.

Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.

The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses.

GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

GRI Bio, Inc.
CountryUnited States
Founded2018
IndustryBiotechnology
SectorHealthcare
Employees4
CEOW. Hertz

Contact Details

Address:
2223 Avenida de la Playa, Suite 208
LA Jolla, California 92037
United States
Phone619 400 1170
Websitegribio.com

Stock Details

Ticker SymbolGRI
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001824293
CUSIP Number3622AW403
ISIN NumberUS3622AW4030
Employer ID82-4369909
SIC Code2834

Key Executives

NamePosition
Dr. W. Marc Hertz Ph.D.Co-Founder, Chief Executive Officer, President and Director
Dr. Vipin Kumar Chaturvedi Ph.D.Co-Founder and Chief Scientific Officer
Leanne M. KellyChief Financial Officer and Corporate Secretary
Dr. Albert Agro Ph.d.Co-Founder and Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Jul 11, 2025ARSFiling
Jul 11, 2025DEF 14AOther definitive proxy statements
Jun 26, 20258-KCurrent Report
May 23, 20258-KCurrent Report
May 23, 2025424B5Filing
May 15, 202510-QQuarterly Report
May 15, 20258-KCurrent Report
May 5, 20258-KCurrent Report
May 5, 2025424B5Filing
Apr 16, 20258-KCurrent Report